Investigators conducted a meta-analysis of randomized controlled trials to assess the efficacy and safety of brolucizumab ...

OCS-01, an eye drop developed by Oculis Holding and currently under phase 3 trials for diabetic macular edema (DME), can be ...

Vision loss occurs in DR due to the development of maculopathy, especially diabetic macular edema, and due to proliferative diabetic retinopathy. Vision loss due to DR is preventable with the ...

India, which is seeing a surge in diabetes cases, is also witnessing a rise in diabetic retinopathy, a condition that damages ...

Articles covering FDA approvals, dry eye disease, and how eye diseases may be linked to falls were among the top 5 most-read ...

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of ...

For the companies, a potential nod in RVO would be a welcome addition to Eylea HD’s label, which currently covers wet ...

Regeneron (REGN) says Eylea HD developed with Bayer (BAYZF) met the main goal in a Phase 3 trial for macular edema following ...